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Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a distinc-
tive skin lymphoma that is characterized by infiltration of neoplastic cy-
totoxic T-cell mimicking panniculitis [1,2]. SPTCL presents with multiple
erythematous subcutaneous nodules, usually in the absence of other sites
of disease. The most common sites of localization are the extremities and
trunk. The nodules range in size from 0.5 cm to several centimeters. The
condition is sometimes associated with fulminant hemophagocytic syn-
drome (HPS), characterized by fever, pancytopenia, hepatosplenomegaly,
and coagulopathy [2-5]. The natural history of SPTCL is highly variable
ranging from a chronic relapsing to a rapidly fatal course. However, if
HPS is present, the prognosis is poor and sometimes fatal despite aggres-
sive chemotherapy [2-5]. 
Treatment strategies for SPTCL with HPS remain controversial be-
cause of the rarity of this condition. Anthracycline-based regimens, cy-
clophosphamide, doxorubicin, vincristine and prednisone (CHOP) or
CHOP-like combinations have been used most frequently for patients
with aggressive disease, but the overall outcome remains poor [3]. Al-
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Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare T-cell lymphoma characterized
by involvement of the subcutaneous tissue of neoplastic T lymphocytes. SPTCL with hemophago-
cytic syndrome (HPS) is associated with an aggressive clinical course and treatment of SPTCL
with HPS is not well established. Cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP)
therapy is not successful in most patients suffering from SPTCL with HPS. The role of high dose
chemotherapy followed by hematopoietic stem cell transplantation (HSCT) remains controversial.
We report a case of relapsed SPTCL after CHOP chemotherapy and salvage chemotherapy fol-
lowed by autologous HSCT, which had rapid improvement within weeks after cyclosporine and
prednisolone. Immunosuppressive therapy may be an important and successful treatment option
in SPTCL patients, even though they may have clinically aggressive disease.
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though there are several case reports that show high dose chemotherapy
followed by hematopoietic stem cell transplantation (HSCT) to be effec-
tive in patients with chemotherapy refractory SPTCL, the role of HSCT
has not been fully established [3-5]. We report a 35-year-old woman with
SPTCL complicating HPS diagnosed by histopathology and immuno-
histochemistry. This case showed only transient responses to combination
chemotherapy and autologous HSCT, but displays a sustained complete
remission after a course of cyclosporine with prednisolone.
C ase  R eport
A previously healthy 35-year-old woman presented with intermittent
high fever, chills, and fatigue, as well as multiple and painful subcutaneous
nodules on the lower abdomen for 3 months. Despite treatment with an-
tibiotics and non-steroidal anti-inflammatory drugs, she continued to ex-
perience a spiking fever of 39ﾰC, and the tender nodule increased. Her
medical and family histories were unremarkable. On physical examina-
tion, the patient was pale and febrile. There was moderate splenomegaly
but no lymph node enlargement and hepatomegaly. Skin examination re-
vealed multiple erythematous, tender, and firm subcutaneous plaques of
variable size (12 ￗ 9 cm, 5 ￗ 3 cm) on the lower abdomen. The laboratory
investigation included the following: white blood cell count of 1,800/ʼL,
hemoglobin level of 10.0 g/dL, platelet count of 124,000/ʼL, erythrocyte
sedimentation rate of 48 mm/hr, C-reactive protein of 32.5 mg/L, elevated
transaminase (aspartate aminotransferase of 112 IU/L, alanine amino-
transferase of 51 IU/L), high low-density lipoprotein (1,878 IU/L), high
ferritin (3,249 ʼg/L), triglyceride of 139 mg/dL, and D-dimer of 2.27
ug/mL. Throat, midstream urine, sputum, and blood culture results were
negative. Also, serologic test for syphilis, human immunodeficiency virus,
and hepatitis B and C viruses were negative. However, Ebstine-Barr virus
and cytomegalovirus serologic values revealed evidence of past infection.
Tuberculin and Coombs test were negative. Rheumatoid factor and anti
nuclear antibody were negative as well. Abdominal computed tomogra-
phy revealed multiple ill-defined enhancing subcutaneous nodules in the
abdominal wall (Fig. 1A). Whole body 18F-fludeoxyglucose- positron
emission tomography scan image showed multiple hypermetabolic soft
tissue nodules in the subcutaneous layer all over the body (Fig. 1B). Bone
marrow examination showed increased histiocytes and evidence of he-
mophagocytosis. An excisional biopsy of the nodule from the lower ab-
domen showed the rimming of the lymphoid cells around individual fat
cells. The overlying dermis and epidermis were not involved. Immuno-
histochemistry analysis showed that tumor cells expressed CD3 and CD8
but were negative for CD56 (Fig. 2). T-cell receptor (TCR) (γ chain) gene
rearrangement was negative following polymerase chain reaction analysis.
Although the status of T-cell gene rearrangement was not confirmed, rim-
ming of individual adipocytes by the CD8+ and CD56- neoplastic T-cell
and strict subcutaneous localization were consistent with a diagnosis of
SPTCL.
The patient was treated with CHOP regimen, resulting in the transient
disappearance of the plaques and fever. Two months after completing 6
cycles of chemotherapy, her disease relapsed with multiple nodules on
Fig. 1. Radiologic finding. (A) Abdominal computed tomography shows an enhancing nodule in the subcutaneous layer of the low abdominal
wall. (B) Positron emission tomography shows numerous fludeoxyglucose uptakes in the subcutaneous layer of the whole body.
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both arms. She received 4 additional cycles of ifosfamide, carboplatin,
etoposide regimen. After salvage chemotherapy, complete remission was
achieved, and autologous HSCT was undertaken with a conditioning reg-
imen comprising busulfan, cyclophophamide, and etoposide. Her neu-
trophil and platelet count recovered within 3 weeks and no severe major
organ impairment occurred during HSCT. Four months after the autolo-
gous HSCT, a new lesion on the left breast was confirmed by clinical ex-
amination and biopsy. The patient underwent 2 additional cycles of
chemotherapy and at the end of these cycles returned with multiple ery-
thematous subcutaneous nodules, febrile neutropenia and severe bone
marrow suppression. Therefore, chemotherapy was discontinued. Eight
months after the autologous HSCT, the patient was started on cyclosporine
4 mg/kg/day and prednisone. The fever and other systemic symptoms
and skin lesions resolved within 2 months after the treatment. Prednisone
administration was tapered gradually, and a maintenance dose of cy-
closporine was continued. The patient’s condition remained in complete
remission at 20-month follow-up. There was no evidence of clinical re-
lapse.
Discussio n
Gonzalez et al. [1] first described SPTCL in 1991. It is a rare form of
lymphoma, representing less than 1% of all non-Hodgkin lymphomas.
SPTCL is slightly more common in females than males and has a broad
age range. Some patients present with HPS and the expression of CD56
by tumor cells, both of which are associated with shorter survival [3,4]. It
also had been observed that SPTCL’s clinical course was different de-
pending on the TCR phenotype and immunophenotypic characteristics
of the tumor cells. Therefore, a distinction had been made between cases
Fig. 2. Tumor pathology. (A) Histopathology of subcutaneous nodule showing neoplastic lymphoid cells infiltrating mainly lobular areas of sub-
cutaneous tissue (H&E staining, ￗ400). Immunohistochemical stains showing the rimming of individual fat spaces by tumor cells with staining
for CD3 (B) and CD8 (C) (H&E staining, ￗ400). (D) Tumor cells do not express the CD56 phenotype (H&E staining, ￗ200). 
A B
C DCancer Res Treat. 2011;43(4):255-259
258 CANCER  RESEARCH AND  TREATMENT
with a ʱ/β T-cell phenotype and with a γ/ʴ T-cell phenotype, with the latter
typically expressing the CD56 phenotype and being more aggressive [3-
6]. In the fourth edition of the World Health Organization (WHO) classi-
fication, cases expressing the γ/ʴ TCR are excluded from SPTCL, and
reclassified as primary cutaneous γ/ʴ T-cell lymphoma [2]. Although TCR
rearrangement analysis and immunophenotyping with TCR βF1 were not
available in our patient, rimming of individual adipocytes by the CD8+
and CD56- neoplastic T-cell and strict subcutaneous localization were
consistent with a diagnosis of SPTCL.
The best treatment strategy for SPTCL has not been fully defined be-
cause of its rarity and clinical diversity. In general, immunosuppressive
agents, such as prednisone and cyclosporine, or low-dose chemotherapy
with a single agent were used as the initial treatment for patients who had
a relatively indolent presentation. For patients with a more aggressive dis-
ease, up-front anthracycline-based combination chemotherapy was used
most frequently [3-5]. Because the presence of HPS at diagnosis is one
of the most important prognostic factors that predict poor overall survival,
it may be a parameter that determines whether disease is indolent or ag-
gressive [3,4]. The other factors associated with an unfavorable prognosis
are low white blood cell count or elevated lactate dehydrogenase (LDH)
[5]. Our patient presented multiple subcutaneous lesions, accompanied
with HPS, and had elevated LDH at the time of diagnosis. Her condition
was diagnosed as an aggressive form of SPTCL and she was treated with
CHOP as the first line of treatment. 
There have been conflicting results about the role of up-front anthra-
cycline based combination chemotherapy. An analysis of patients with
SPTCL in the literature reported that CHOP or CHOP-like therapies re-
sulted in an overall response of 53% and median duration of complete re-
mission of more than 11.5 months [3]. In addition, a case report showed
durable remission in SPTCL with HPS after CHOP [7]. However, the re-
port from a workshop of the European Organisation for Research and
Treatment of Cancer Cutaneous Lymphoma Group showed only two of
11 SPTCL patients with HPS exhibited durable survival after CHOP(-
like)  therapies  [4]. These  results  indicate  that  anthracycline  based
chemotherapy is not very successful in patients with SPTCL with associ-
ated HPS. In this case, although she achieved complete remission during
CHOP therapy, the duration of remission was short. Anthracycline based
combination chemotherapy as first line treatment in SPTCL patients with
HPS should be questioned.
Autologous HSCT is the standard consolidation treatment after salvage
chemotherapy in a relapsed lymphoma, provided the lymphoma has been
chemosensitive to the conventional salvage chemotherapy regimen. How-
ever, the role of autologous HSCT in the SPTCL has not been clarified
because most information comes from case series. Some patients with
SPTCL have recently undergone high dose chemotherapy followed by
autologous HSCT, and most of them achieved complete remission with
a median follow-up of 14 months [4,5,8-10], but the possibility that failure
after HSCT may be under-reported can not be ruled out. In the present
case, the patient only had transient remission after autologous HSCT, even
though she had a complete remission during salvage chemotherapy. 
Our patient showed only transient responses to CHOP and high-dose
chemotherapy, but displayed a marked complete remission after cy-
closporine and prednisolone without subsequent chemotherapy. Cy-
closporine had been suggested as a potentially effective agent in the
treatment of angioimmunoblastic T-cell lymphoma, a disease with con-
siderable immune dysregulation [11]. Several reports suggest that patients
with SPTCL without HPS may benefit from variable immunosuppressive
agents including cyclosporine and steroid [4,12,13]. Serum levels of in-
terferon γ and soluble interleukin-2 receptor were elevated during the ac-
tive disease and normalized after cyclosporine, suggesting that cytokine
upregulation and modulation may be the pathophysiology of SPTCL as
well as the mechanism of action of this drug [13]. However, to our knowl-
edge, this is the first report which shows the efficacy of cyclosporine in
relapsed SPTCL with HPS after HSCT. This result suggests that patients
with SPTCL may benefit from immunosuppressive therapy even though
it is a clinically aggressive disease. Further study on novel therapeutic
strategies, including cyclosporine containing immunosuppression as a
first line of treatment, is needed to improve the clinical outcome of SPTCL
with HPS.
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